Key result
Mavacamten linked to functional class improvement in ~73% of obstructive hypertrophic cardiomyopathy patients.
Why the study?
Previous studies demonstrated the efficacy and safety of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy primarily outside of Canada, leaving limited Canadian real-world evidence.
Does mavacamten improve NYHA functional class and reduce LVOT gradients in Canadian patients with symptomatic obstructive hypertrophic cardiomyopathy in routine clinical practice?
Observational (n=115)
Yes
Does mavacamten improve NYHA functional class and reduce LVOT gradients in Canadian patients with symptomatic obstructive hypertrophic cardiomyopathy in routine clinical practice?
In this first Canadian real-world cohort study of patients with symptomatic obstructive hypertrophic cardiomyopathy, mavacamten was associated with clinically meaningful improvements in NYHA functional class and LVOT gradients with a low rate of LVEF reduction < 50% and no cases of LVEF < 30%, even without a mandatory REMS program or CYP2C19 genotyping.
Answers are grounded in this paper and cite their sources.
Real-world Canadian data support mavacamten effectiveness in symptomatic oHCM; extends RCT findings while leaving long-term outcomes open.
Introduction Previous studies have demonstrated the efficacy and safety of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), primarily outside of Canada, with limited Canadian real-world data evidence. The MAVEN study aimed to describe the real-world effectiveness of mavacamten in Canadian patients with oHCM. Methods This multi-center, retrospective physician survey of patient charts included 115 patients with oHCM who initiated mavacamten between January 2023 and November 2024 across five Canadian sites. Effectiveness was assessed by changes in clinical characteristics and outcomes, including New York Heart Association (NYHA) functional class, resting and Valsalva left ventricular outflow tract (rLVOT and vLVOT, respectively) gradients, and left ventricular ejection fraction (LVEF), from treatment initiation to the most recent available assessment. Results Baseline demographic and clinical characteristics were consistent with previously published data (median age 63.0 years; 66.1% aged ≥ 60 years; 51.3% male, 48.7% female patients; 57.4% NYHA class II, 42.6% NYHA class III). Median baseline rLVOT and vLVOT gradients were 44.0 and 78.0 mmHg, respectively, and median LVEF was 65.0%. Overall, 72.7% of patients improved by ≥ 1 NYHA functional class. Median reductions in rLVOT and vLVOT gradients were − 25.5 (interquartile range [IQR]: − 61, − 8) mmHg and − 51.0 (IQR: − 83, − 24) mmHg, respectively, while median LVEF changed by − 3.0% (IQR: − 8, 0). Mavacamten was discontinued in 8.7% of patients, including 2.6% due to treatment-emergent adverse events. Reductions in LVEF < 50% were observed in 6.1% of patients, and no patient experienced an LVEF < 30%. Conclusions In this first Canadian real-world study of mavacamten effectiveness, treatment was associated with improvements in symptoms and LVOT obstruction. Reductions in LVEF < 50% were observed in a minority of patients, with no cases of LVEF < 30%. Given the retrospective design and heterogeneous follow-up of this study, these findings should be interpreted cautiously. Graphical abstract available for this article.
No takes yet. Share an insight, caveat, or question.
Ward et al. (2026) conducted an observational in Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) (n=115). Mavacamten was evaluated on Improvement of >= 1 New York Heart Association (NYHA) functional class from baseline to most recent assessment. Mavacamten was associated with an improvement of >=1 functional class in 72.7% of oHCM patients and median resting and Valsalva LVOT gradient reductions of 25.5 and 51.0 mmHg.
Synapse has enriched 10 related papers. Consider them for comparative context: